Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Remibrutinib by Novartis for Peanut Allergy: Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase II for Peanut Allergy. According to GlobalData, Phase II...
Remibrutinib by Novartis for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to...
Remibrutinib by Novartis for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Novartis's Remibrutinib?
Remibrutinib is a small molecule commercialized by Novartis, with a leading Phase III program in Chronic Urticaria Or Hives. According...
Remibrutinib by Novartis for Hidradenitis Suppurativa: Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Remibrutinib by Novartis for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According to...
Remibrutinib by Novartis for Chronic Urticaria Or Hives: Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase III for Chronic Urticaria Or Hives. According to GlobalData,...